Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities

Journal of the American Podiatric Medical Association

Volumn 102, Issue 3, 2012, Pages 233-239

  Lullove, Eric ^a  

^a Private Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861871106     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/1020233     Document Type: Article

References (39)

1. Bello YM, Falabella AF, Eaglstein WH: Tissue-engineered skin: current status in wound healing. Am J Clin Dermatol 2: 305, 2001.
2. Brem H, Balledux J, Bloom T, et al: Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 135: 627, 2000.
3. Edmonds M: Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 8: 11, 2009.
4. Gentzkow GD, Iwasaki SD, Hershon KS, et al: Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 19: 350, 1996.
5. Marston WA, Hanft J, Norwood P, et al: The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26: 1701, 2003.
6. Veves A, Falanga V, Armstrong DG, et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24: 290, 2001.
7. Falanga V, Sabolinski M: A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7: 201, 1999.
8. Advanced BioHealing Inc: Dermagraft Human Fibro-blast-Derived Dermal Substitute: Directions for Use, Advanced BioHealing Inc, Westport, CT, 2007.
9. Organogensis Inc: Apligraf Prescribing Information, Organogensis Inc, Canton, MA, March 2010.
10. Healthpoint Ltd/Cook Biotech Inc: OASIS Wound Matrix: Instructions for Use, Healthpoint Ltd, San Antonio, TX, 2006.
11. Wright Medical Technology Inc/LifeCell Corp: GRAFT-JACKET Regenerative Tissue Matrix: Instructions for Use, Wright Medical Technology Inc, Arlington, TN, August 2009.
12. Brigido SA: The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J 3: 181, 2006.
13. Brigido SA, Boc SF, Lopez RC: Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics 27 (suppl): s145, 2004.
14. Martin BR, Sangalang M, Wu S, et al: Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J 2: 161, 2005.
15. Niezgoda JA, Van Gils CC, Frykberg RG, et al: Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 18: 258, 2005.
16. Reyzelman A, Crews RT, Moore JC, et al: Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 6: 196, 2009.
17. Mostow EN, Haraway GD, Dalsing M, et al: Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg 41: 837, 2005.
18. Romanelli M, Dini V, Bertone MS: Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care 23: 34, 2010.
19. Cornwell KG, Landsman A, James KS: Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg 26: 507, 2009.
20. Valentin JE, Badylak JS, McCabe GP, et al: Extracellular matrix bioscaffolds for orthopaedic applications: a comparative histologic study. J Bone Joint Surg Am 88: 2673, 2006.
21. Cook JL, Fox DB, Kuroki K, et al: In vitro and in vivo comparison of five biomaterials used for orthopedic soft tissue augmentation. Am J Vet Res 69: 148, 2008.
22. Ruszczak Z: Effect of collagen matrices on dermal wound healing. Adv Drug Deliv Rev 55: 1595, 2003.
23. Adzick NS, Harrison MR, Glick PL, et al. Comparison of fetal, newborn, and adult wound healing by histologic, enzyme-histochemical, and hydroxyproline determinations. J Pediatr Surg 20: 315, 1985.
24. Bullard KM, Longaker MT, Lorenz HP: Fetal wound healing: current biology. World J Surg 27: 54, 2003.
25. Longaker MT, Bouhana KS, Harrison MR, et al: Wound healing in the fetus: possible role for inflammatory macrophages and transforming growth factor-b iso-forms. Wound Repair Regen 2: 104, 1994.
26. Larson BJ, Longaker MT, Lorenz HP: Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 126: 1172, 2010.
27. Karr JC: Retrospective Comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). Adv Skin Wound Care 24: 119, 2011.
28. Higgs WR: Repair of a fifth finger crush injury. Wound Care Hyperbaric Med 1: 9, 2010.
29. Dunckel A: Acellular bovine-derived matrix used on a traumatic crush injury of the hand: a case study. Ostomy Wound Manage 55: 44, 2009.
30. Wanitphakdeedecha R, Chen TM, Nguyen TH: The use of acellular, fetal bovine dermal matrix for acute, full-thickness wounds. J Drugs Dermatol 7: 781, 2008.
31. Higgs WR: Necrotizing fasciitis with delayed closure. Wound Care Hyperbaric Med 1: 8, 2010.
32. Neil J, James K, Lineaweaver W: Utilizing biologic assimilation of bovine fetal collagen in complex reconstruction. Paper presented at: Annual Scientific Conference of the Southeastern Society of Plastic and Reconstructive Surgeons; June 4-8, 2011; Naples, FL.
33. Frykberg RG, Zgonis T, Armstrong DG, et al: Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg 45 (suppl): S1, 2006.
34. Margolis DJ, Kantor J, Berlin JA: Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22: 692, 1999.
35. Apelqvist J, Armstrong DG, Lavery LA, et al: Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg 195: 782, 2008.
36. Driver VR, De Leon JM: Health economic implications for wound care and limb preservation. J Managed Care Med 11: 13, 2008.
37. Redekop WK, McDonnell J, Verboom P, et al: The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 21: 1171, 2003.
38. Stockl K, Vanderplas A, Tafesse E, et al: Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 27: 2129, 2004.
39. Bolton LL, Van Rijswijk L, Shaffer FA: Quality wound care equals cost-effective wound care: a clinical model. Nurs Manage 30: 32, 1996.